03/24
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
03/24
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
02/24
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
02/24
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
11/23
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
10/23
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
10/23
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
10/23
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
09/23
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
08/23
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
07/23
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
06/23
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
06/23
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
06/23
MoonLake R&D Day - Phase 2 Results MIRA Trial
06/23
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
05/23
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
04/23
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
03/23
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
02/23
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
12/22
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
11/22
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
11/22
We are thrilled to announce that MoonLake has been awarded the European Lifestars Awards - Celebrating Life Science Executives & their partners Lifestars Awards ‘Post-IPO Equity Raise of the Year’ Award in recognition of our successful business combination and fundraising this year.
09/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
07/22
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
05/22
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
05/22
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
04/22
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.
03/22
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint
10/21
MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab
08/21
MoonLake Immunotherapeutics appoints former Kymab CEO Simon Sturge as Chairman and Spike Loy to the Board of Directors
07/21
MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO
05/21
MoonLake Immunotherapeutics announces publication in The Lancet
05/21
MoonLake In-licensing and launch